Cancer Care During the COVID-19 Pandemic: A Retrospective Study From a Najran Oncology Center

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: June 26, 2024

Background The COVID-19 pandemic significantly impacted healthcare systems globally, with cancer patients representing a particularly vulnerable group. This study aims to evaluate the influence of on cancer, focusing infection rates, types care, therapy adjustments, and factors associated infection. Materials methods single-center retrospective analysis included adult who underwent anticancer at King Khalid Hospital in Najran, Saudi Arabia, from December 20, 2020, January 23, 2022. Data patient characteristics, specifics, treatment delays, outcomes, were collected analyzed. Results A total 257 chemotherapy recipients interviewed. mean age was 52.6 ± 14.4 years, 44 (17.1%) over 65 years old. Females comprised 160 (62.3%) patients. most common malignancies gastrointestinal (71, 27.6%), breast (70, 27.2%), hematological (50, 19.5%). Metastasis present 116 (45.1%). Common comorbidities diabetes (68, 26.5%) hypertension (55, 21.4%). Most (226, 87.9%) vaccinated against COVID-19. tested positive 22 (8.6%), lower rate (7 vs. 15, p < 0.001). cases mild (18, 81.8%), fever (19, 7.4%) cough fatigue (17, 6.6%) being symptoms. median time resume post-infection 30 days. Factors higher rates (OR: 4.73, 95% CI: 1.94-12.03, = 0.001), coronary artery disease 4.13, 1.07-13.30, 0.049), chronic lung 15.58, 5.37-45.79, liver 7.64, 2.38-22.98, multiple 2.04, 1.46-2.90, received 1.02, 0.12-12.79, 0.027), immunotherapy 3.37, CI:1.27-8.43, 0.012). Conclusion incidence is proportional prevalence general population similar geographic areas. Diabetes, disease, receiving or immunotherapy, rates.

Language: Английский

Clinical characteristics and antibody response to Omicron variants among solid carcinoma patients in China on the 2022.12–2023.4 wave of the COVID-19 pandemic

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 6, 2024

Background China experienced a surge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variants after adjusting its zero-coronavirus disease 2019 (COVID-19) policy. Although infections with are generally less than previous SARS-CoV-2 variants, the clinical characteristics, persistent symptoms, and antibody responses in solid carcinoma patients (SCPs) COVID-19 during wave unclear. Methods We conducted cross-sectional study April 2023, recruiting healthy controls (HCs) from community SCPs Zhejiang Provincial People’s Hospital. Serum samples were collected, questionnaire was used to assess infection status, including demographic manifestations, “long COVID” symptoms. Humoral immune analyzed by enzyme-linked immunosorbent assays (ELISAs) targeting immunoglobulin G (IgG) antibodies against receptor-binding domain (RBD; BA.4/5) protein cell culture-based neutralization (BA.4/5, BF.7, XBB.1.5, EG.5). Results In total, 298 258 HCs enrolled. Self-reported case rates significantly lower (78.5% vs. 93.8%, P&lt;0.001). Common symptoms similar between two groups, primarily comprising general (92.6% 84.9%) (51.9% 48.2%) infection. There no significant difference at 1–3 months post-infection (P=0.353); fatigue most common symptom (45.0% 44.8%). exhibited anti-RBD-IgG titers compared (1.061 1.978, P=0.001). The 50% pseudovirus titer (pVNT 50 ) values for prevalent strains (BA.4/5 BF.7) (621.0 [288.8, 1333.0] 894.1 [458.5, 1637.0] 529.6 [215.3, 1264.5] 463.1 [185.2, 914.0], respectively). Levels subsequent (XBB.1.5 EG.5) also reduced. differences among types levels variants. However, who received vaccine or had displayed higher levels. Conclusions This elucidated immunological characteristics shift away zero-COVID-19 Our findings provide insights regarding factors that influence this population.

Language: Английский